Research Analysts Offer Predictions for Heron Therapeutics Inc’s Q2 2017 Earnings (HRTX)
Heron Therapeutics Inc (NASDAQ:HRTX) – Investment analysts at Jefferies Group cut their Q2 2017 EPS estimates for shares of Heron Therapeutics in a report issued on Wednesday. Jefferies Group analyst B. Amin now anticipates that the biotechnology company will post earnings of ($0.99) per share for the quarter, down from their previous estimate of ($0.90). Jefferies Group has a “Buy” rating and a $29.00 price target on the stock. Jefferies Group also issued estimates for Heron Therapeutics’ Q3 2017 earnings at ($0.99) EPS, Q4 2017 earnings at ($0.99) EPS, FY2017 earnings at ($3.89) EPS, FY2018 earnings at ($2.30) EPS, FY2019 earnings at ($0.95) EPS, FY2020 earnings at $0.71 EPS and FY2021 earnings at $2.04 EPS.
A number of other equities analysts have also issued reports on the company. Noble Financial reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Friday. Cantor Fitzgerald reaffirmed a “buy” rating and set a $31.00 price target (up from $30.00) on shares of Heron Therapeutics in a research note on Thursday. Zacks Investment Research lowered Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 9th. Aegis reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Tuesday, March 21st. Finally, Needham & Company LLC assumed coverage on Heron Therapeutics in a research note on Monday, February 27th. They set a “buy” rating and a $28.00 price target for the company. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $34.50.
Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 14.60 on Monday. The firm has a 50-day moving average price of $14.88 and a 200 day moving average price of $14.62. Heron Therapeutics has a one year low of $12.21 and a one year high of $24.00.
Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Wednesday, May 10th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.94) by $0.06. The business had revenue of $3.63 million during the quarter, compared to the consensus estimate of $1.96 million.
Several large investors have recently made changes to their positions in HRTX. Legal & General Group Plc increased its stake in shares of Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after buying an additional 1,098 shares during the period. Venturi Wealth Management LLC bought a new stake in shares of Heron Therapeutics during the first quarter worth approximately $161,000. Wells Fargo & Company MN increased its stake in shares of Heron Therapeutics by 20.0% in the third quarter. Wells Fargo & Company MN now owns 11,167 shares of the biotechnology company’s stock worth $192,000 after buying an additional 1,858 shares during the period. Pacad Investment Ltd. bought a new stake in shares of Heron Therapeutics during the fourth quarter worth approximately $155,000. Finally, Old West Investment Management LLC bought a new stake in shares of Heron Therapeutics during the first quarter worth approximately $206,000.
In other news, VP Kimberly Manhard sold 21,542 shares of the stock in a transaction on Monday, April 24th. The stock was sold at an average price of $15.33, for a total transaction of $330,238.86. Following the completion of the sale, the vice president now owns 5,250 shares in the company, valued at approximately $80,482.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 20.31% of the stock is currently owned by corporate insiders.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.